FDA Accepts Ultragenyx's UX111 Gene Therapy Resubmission, Sets September PDUFA for Sanfilippo Syndrome
Summary
The U.S. FDA has accepted Ultragenyx's Biologics License Application (BLA) resubmission for UX111 AAV gene therapy, a potential first-in-class treatment for Sanfilippo Syndrome Type A (MPS IIIA). This acceptance sets a Prescription Drug User Fee Act (PDUFA) action date of September 19, 2026. This development is highly significant as it reverses the prior setback noted in the company's 10-K filing, which disclosed an Incomplete Response Letter for the initial UX111 BLA. The re-acceptance and establishment of a PDUFA date provide a clear regulatory pathway and timeline for a key pipeline asset targeting a rare, fatal disease with no approved treatments. Traders will closely monitor the PDUFA date for the final approval decision, which could materially impact the company's valuation.
At the time of this announcement, RARE was trading at $19.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.1B. The 52-week trading range was $18.29 to $42.37. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.